FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3012080550> ?p ?o ?g. }

• W3012080550 endingPage "879" @default.
• W3012080550 startingPage "870" @default.
• W3012080550 abstract "Summary Background Tacrolimus is a calcineurin inhibitor commonly used for prophylaxis of rejection in renal and liver transplantation. There are limited but favourable data regarding its possible use in patients with inflammatory bowel disease (IBD). Aims To evaluate the efficacy and safety of tacrolimus in patients with IBD in clinical practice. Methods We performed a retrospective, multicentre study in 22 centres in Spain. All adult patients who received oral tacrolimus for luminal or perianal IBD were included. Clinical response was assessed by Harvey‐Bradshaw index and partial Mayo score after 3 months. Perianal disease was evaluated by fistula drainage assessment. Results One hundred and forty‐three patients were included (mean age 38 years; 51% male; median disease duration 110 months). In ulcerative colitis (UC) (n = 58), the partial Mayo score decreased after 3 months from median 6 to 3 ( P = 0.0001), whereas in Crohn's disease (CD) (n = 85), the Harvey‐Bradshaw index decreased after 3 months from median 9 to 7 ( P = 0.011). In CD patients, blood tacrolimus concentrations during induction (>10 ng/mL vs <10 ng/mL; odds ratio 0.23, 95% CI 0.05‐0.87) and the concomitant use of thiopurines (odds ratio 0.18, 95% CI 0.04‐0.81) were associated with lower clinical disease activity at 3 months. Of 62 patients with perianal disease, complete closure was observed in 8% (n = 5) of patients with perianal fistulas, with 34% (n = 21) showing partial response. Treatment was maintained for a median of 6 months (IQR, 2‐16). After a median clinical follow‐up of 24 months (IQR, 15‐57), the rate of treatment‐related adverse events was 34%, correlating with blood drug concentrations ( P = 0.021). Finally, 120 patients (84%) discontinued tacrolimus, usually due to absence or loss of response. Three patients (2%) were subsequently diagnosed with cancer. The overall rate of surgery was 39%, with a 33% colectomy rate in UC. Conclusions Tacrolimus shows a clinical benefit in both CD and UC after 3 months of treatment, but its long‐term effectiveness and frequent adverse events remain relevant issues in clinical practice." @default.
• W3012080550 created "2020-03-23" @default.
• W3012080550 creator A5000889870 @default.
• W3012080550 creator A5001406662 @default.
• W3012080550 creator A5007019089 @default.
• W3012080550 creator A5011184219 @default.
• W3012080550 creator A5011718094 @default.
• W3012080550 creator A5013238742 @default.
• W3012080550 creator A5017286678 @default.
• W3012080550 creator A5028941216 @default.
• W3012080550 creator A5031350614 @default.
• W3012080550 creator A5034203747 @default.
• W3012080550 creator A5042359977 @default.
• W3012080550 creator A5045641131 @default.
• W3012080550 creator A5048489661 @default.
• W3012080550 creator A5049458972 @default.
• W3012080550 creator A5049758158 @default.
• W3012080550 creator A5050057553 @default.
• W3012080550 creator A5050705694 @default.
• W3012080550 creator A5050877302 @default.
• W3012080550 creator A5071068114 @default.
• W3012080550 creator A5074679114 @default.
• W3012080550 creator A5079935064 @default.
• W3012080550 creator A5080027468 @default.
• W3012080550 creator A5085622666 @default.
• W3012080550 creator A5089237494 @default.
• W3012080550 creator A5090119981 @default.
• W3012080550 date "2020-03-17" @default.
• W3012080550 modified "2023-10-18" @default.
• W3012080550 title "Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease" @default.
• W3012080550 cites W1752248076 @default.
• W3012080550 cites W1994084334 @default.
• W3012080550 cites W2001987698 @default.
• W3012080550 cites W2008908364 @default.
• W3012080550 cites W2022661087 @default.
• W3012080550 cites W2036807791 @default.
• W3012080550 cites W2045737447 @default.
• W3012080550 cites W2048251542 @default.
• W3012080550 cites W2051554586 @default.
• W3012080550 cites W2061736459 @default.
• W3012080550 cites W2091385020 @default.
• W3012080550 cites W2093985240 @default.
• W3012080550 cites W2102804688 @default.
• W3012080550 cites W2104097403 @default.
• W3012080550 cites W2110931337 @default.
• W3012080550 cites W2115149092 @default.
• W3012080550 cites W2139806430 @default.
• W3012080550 cites W2166143228 @default.
• W3012080550 cites W2173653588 @default.
• W3012080550 cites W2200172641 @default.
• W3012080550 cites W2205882029 @default.
• W3012080550 cites W2321205867 @default.
• W3012080550 cites W2517727789 @default.
• W3012080550 cites W2523706394 @default.
• W3012080550 cites W2583633660 @default.
• W3012080550 cites W4292958705 @default.
• W3012080550 doi "https://doi.org/10.1111/apt.15687" @default.
• W3012080550 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32181930" @default.
• W3012080550 hasPublicationYear "2020" @default.
• W3012080550 type Work @default.
• W3012080550 sameAs 3012080550 @default.
• W3012080550 citedByCount "9" @default.
• W3012080550 countsByYear W30120805502020 @default.
• W3012080550 countsByYear W30120805502021 @default.
• W3012080550 countsByYear W30120805502022 @default.
• W3012080550 countsByYear W30120805502023 @default.
• W3012080550 crossrefType "journal-article" @default.
• W3012080550 hasAuthorship W3012080550A5000889870 @default.
• W3012080550 hasAuthorship W3012080550A5001406662 @default.
• W3012080550 hasAuthorship W3012080550A5007019089 @default.
• W3012080550 hasAuthorship W3012080550A5011184219 @default.
• W3012080550 hasAuthorship W3012080550A5011718094 @default.
• W3012080550 hasAuthorship W3012080550A5013238742 @default.
• W3012080550 hasAuthorship W3012080550A5017286678 @default.
• W3012080550 hasAuthorship W3012080550A5028941216 @default.
• W3012080550 hasAuthorship W3012080550A5031350614 @default.
• W3012080550 hasAuthorship W3012080550A5034203747 @default.
• W3012080550 hasAuthorship W3012080550A5042359977 @default.
• W3012080550 hasAuthorship W3012080550A5045641131 @default.
• W3012080550 hasAuthorship W3012080550A5048489661 @default.
• W3012080550 hasAuthorship W3012080550A5049458972 @default.
• W3012080550 hasAuthorship W3012080550A5049758158 @default.
• W3012080550 hasAuthorship W3012080550A5050057553 @default.
• W3012080550 hasAuthorship W3012080550A5050705694 @default.
• W3012080550 hasAuthorship W3012080550A5050877302 @default.
• W3012080550 hasAuthorship W3012080550A5071068114 @default.
• W3012080550 hasAuthorship W3012080550A5074679114 @default.
• W3012080550 hasAuthorship W3012080550A5079935064 @default.
• W3012080550 hasAuthorship W3012080550A5080027468 @default.
• W3012080550 hasAuthorship W3012080550A5085622666 @default.
• W3012080550 hasAuthorship W3012080550A5089237494 @default.
• W3012080550 hasAuthorship W3012080550A5090119981 @default.
• W3012080550 hasConcept C126322002 @default.
• W3012080550 hasConcept C128057223 @default.
• W3012080550 hasConcept C141071460 @default.
• W3012080550 hasConcept C156957248 @default.
• W3012080550 hasConcept C167135981 @default.
• W3012080550 hasConcept C2778260677 @default.

• next